Now Accepting Nominations
2025 Harrington Prize for Innovation in Medicine
September 11, 2024
OXFORD, UK and CLEVELAND, Ohio, US, 11th September 2024 – The Oxford-Harrington Rare Disease Centre (‘OHC’), a partnership between the University of Oxford, UK and Harrington Discovery Institute at University Hospitals, Cleveland, Ohio, aimed at driving cutting-edge rare disease breakthroughs, announces the...
Continue Reading
May 01, 2023
Atsena Therapeutics announced that the FDA has cleared the company’s IND application for a Phase I/II clinical trial of ATSN-201 in patients with X-linked retinoschisis (XLRS), featuring Harrington Scholar Shannon Boye, PhD, University of Florida. Continue Reading
April 26, 2023
10 physician-scientists have been selected for drug development grant to advance discoveries into the clinic Continue Reading
April 10, 2023
Unique program for physician-scientists to advance promising discoveries into medicines Continue Reading
April 03, 2023
Focus on glymphatic clearance, neurovascular health, and other novel approaches Continue Reading
March 07, 2023
2023 Harrington Prize for Innovation in Medicine Recognizes Pioneering Work in Retinal Gene Therapy for Genetic Diseases Continue Reading
March 01, 2023
Newfound clarity on the longstanding “medical mystery” may lead to new line of drugs for oxygen delivery disorders, including peripheral artery disease, sickle cell disease, heart failure, and others Continue Reading
February 14, 2023
Thylacine Biotherapeutics Inc. entered into a license agreement with Columbia University for worldwide exclusive rights to develop and commercialize a novel antiviral peptide platform. Continue Reading
January 27, 2023
Sol-Gel Technologies, Ltd. announced today the acquisition of topically-applied patidegib, a hedgehog signaling pathway blocker, for the treatment of Gorlin syndrome from PellePharm, Inc. Continue Reading
January 24, 2023
A team led by investigators at Massachusetts General Hospital (MGH), including Marc Wein, MD, PhD, Massachusetts General Hospital, 2018 Harrington Scholar-Innovator, might lead to a new, more convenient drug for preventing and treating osteoporosis. Continue Reading
January 12, 2023
Dr. Christiane Wrann of Massachusetts General Hospital selected for research aimed at using the novel exercise hormone irisin to treat Alzheimer’s disease Continue Reading